Lupartumab (BAY 1112623) CAS 1640971-88-5
Lupartumab is a human IgG1κ monoclonal antibody that targets LYPD3 (C4.4A), a protein overexpressed in various cancers, including non-small cell lung cancer (NSCLC).
Key Features:
- Target Specificity: Binds to LYPD3 (C4.4A), which is expressed on tumor cells.
- Mechanism of Action: Help to create antibody-drug conjugates (ADCs) that deliver cytotoxic agents directly to LYPD3-expressing tumor cells.
- Therapeutic Potential: Being studied for the treatment of cancers such as NSCLC.
Applications:
- Cancer Research: Key in developing ADCs targeting LYPD3-expressing tumors, increasing treatment precision while minimizing systemic toxicity.
- ADC Development: Lupartumab can help synthesize ADCs like BAY 1129980, which has shown promise in preclinical studies against LYPD3-positive tumors.
Handling and Storage:
- Storage: Keep at -20°C, protected from light.
- Precautions: Wear appropriate protective equipment and ensure proper ventilation during handling.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
